
Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease1 that requires a lifelong struggle for those who have it. Despite the fact that there are 43 cases of lupus per 100,000 people in Malaysia,2 the disease is underdiagnosed, leaving lupus patients and their caregivers to fight the disease alone. The Malaysian SLE Association (PSLEM) and the Malaysian Society of Rheumatology (MSR) have teamed up with AstraZeneca to launch #UnlockingLupus, a public awareness campaign aimed at promoting early diagnosis and lupus awareness.

The #UnlockingLupus campaign was launched in conjunction with World Lupus Day, and it was officiated by Dr. Izzuna Mudla Mohamed Ghazali, Deputy Director, Malaysian Health Technology Assessment Section, Medical Development Division, Ministry of Health. Also present were Dr. Heselynn Hussein, President of the Malaysian SLE Association, Dr. Syahrul Sazliyana, UKM Rheumatologist and a representative of the Malaysian Society of Rheumatology, and Bernice Chan, Chief Marketing Officer of AstraZeneca.

AstraZeneca is supporting a microsite that was specifically created for the #UnlockingLupus campaign and is located at www.unlockinglupusmy.com. The microsite acts as a one-stop resource for information on lupus, offering the general public resources for everything from diagnosis to treatment.

From the physical symptoms to the emotional struggles that come with having lupus, it is a constant battle for patients with lupus, their caregivers and loved ones. We believe the best way to support them is to spread awareness through this collaborative campaign that shares more insights on lupus, and how the public can support the patients and caregivers.
said Dr Heselynn Hussein, President of the Malaysian SLE Association

Dr. Heselynn asserts that PSLEM offers an SLE fund to which patients can apply for assistance. Lupus cannot be cured, but with the right care and support, the condition can be controlled. The available treatments help manage the “butterfly” flares while ensuring minimal organ damage, depending on the type and severity of symptoms.
As part of its ongoing efforts to educate the public about lupus, PSLEM organised the “Walk-a-Payung for Lupus” event in conjunction with the recent World Lupus Day on May 10 with the help of AstraZeneca. The walk with umbrellas serves as a metaphor for the support and safety lupus patients need, as well as the effects lupus has on parents and their support network.

Our aim is to help patients be heard and supported in this silent battle. Living with lupus is challenging as it takes a toll on the body and mind. With the campaign microsite, we invite everyone to learn more about lupus, where a diagnosis can be
said Dr Syahrul Sazliyana, UKM Rheumatologist and a representative of the Malaysian Society of Rheumatology
challenging as the symptoms are often hidden away.

Speaking from the perspective of a lupus patient, 66-year-old Jean Chan indicated that lupus has taught her to be resilient. She has lived with lupus for the past 29 years. The constant support, encouragement, care, and love given to the patient is the most crucial element in helping them overcome their negative feelings about having this debilitating illness.

Many living with lupus face challenges with diagnosis, unpredictable disease flares and limited care options. Globally, lupus places a heavy physical, emotional and financial burden on the 5 million people living with the condition. At AstraZeneca, we are working towards a future where people living with lupus have access to quality care. This goal is being advanced through scientific innovation, stronger collaboration with the lupus community, and an increased focus on health equity.
explained Bernice Chan, Chief Marketing Officer, AstraZeneca
Bernice added that their goal is to collaborate with associations using a partnership-driven strategy to educate the public about this chronic illness, encourage early diagnosis, and encourage treatment seeking. Together, they can work to raise the bar for treatment and ultimately help people with lupus live more fully.

Lupus is a chronic illness that can be managed with effective care and a positive environment. Visit www.unlockinglupusmy.com for more information about lupus.
Malaysian SLE Organisation (PSLEM)
PSLEM is a non-profit charitable organisation. It was set up in 1994 by doctors and patients to support people living with systemic lupus erythematosus (SLE), and to also promote public understanding of SLE and related Mixed Connective Tissue Disease (MCTD).
Malaysian Society of Rheumatology (MSR)
MSR is a professional society for rheumatologists in Malaysia, that aims to promote the growth of rheumatology as a specialty, improve the state of management of rheumatic diseases, and drive awareness for arthritis awareness among professionals and the public.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter, Instagram and Facebook

About SLE
Systemic Lupus Erythematosus (SLE)
SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body.3 It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms, including pain, rashes, fatigue, and swelling in joints and fevers.4 Approximately half of all patients with SLE will have some form of organ damage within 10 years of their diagnosis caused by the disease or existing treatments, which exacerbates symptoms and increases the risk of mortality.3,5,6

References
1. American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis & Rheumatology. 1999; 42: 1785-1796.
2. Chai, H. K., Phipps, M. E., & Chua, K. H. (2012). Genetic Risk Factors of Systemic Lupus Erythematosus in the Malaysian Population: A Minireview. Clinical & Developmental Immunology, 2012, 1. https://doi.org/10.1155/2012/963730
3. Bruce IN, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015; 74: 1706-1713
4. American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis & Rheumatology. 1999; 42: 1785-1796.
5. Segura BT, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatol. 2020; 59 (3): 524-533.
6. Chambers SA, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatol. 2009; 48: 673-675.